<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000708</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 059</org_study_id>
    <secondary_id>Protocol 159</secondary_id>
    <secondary_id>Project 056</secondary_id>
    <secondary_id>Investigator 556</secondary_id>
    <nct_id>NCT00000708</nct_id>
  </id_info>
  <brief_title>Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis</brief_title>
  <official_title>Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To compare the safety and effectiveness of fluconazole (FCZ) and amphotericin B (AMB), alone&#xD;
      or in combination with flucytosine (FLC), as treatment for acute cryptococcal meningitis in&#xD;
      patients who have not been treated previously or who have relapsed after a previous&#xD;
      successful treatment.&#xD;
&#xD;
      Cryptococcal meningitis is an important cause of disease and death among patients with AIDS.&#xD;
      Usually AMB is given either alone or with FLC to patients with this infection, but these&#xD;
      treatments are not always effective and both have toxic effects. Animal studies and&#xD;
      preliminary studies in humans show that FCZ is active in cryptococcal meningitis and suggest&#xD;
      that it may be less toxic than either AMB or FLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cryptococcal meningitis is an important cause of disease and death among patients with AIDS.&#xD;
      Usually AMB is given either alone or with FLC to patients with this infection, but these&#xD;
      treatments are not always effective and both have toxic effects. Animal studies and&#xD;
      preliminary studies in humans show that FCZ is active in cryptococcal meningitis and suggest&#xD;
      that it may be less toxic than either AMB or FLC.&#xD;
&#xD;
      Patients accepted into the study are randomly assigned to FCZ or AMB. Patients assigned to&#xD;
      FCZ take FCZ by mouth daily for 10 weeks. Patients assigned to AMB are given intravenous&#xD;
      injections of AMB daily for 6-10 weeks. Non-AIDS patients assigned to AMB also take FLC by&#xD;
      mouth daily. The use of FLC in patients with AIDS is decided on an individual basis. Patients&#xD;
      with AIDS who respond satisfactorily to FCZ receive maintenance therapy to prevent relapse&#xD;
      for an additional 12 months. Patients with AIDS who respond to AMB may qualify for another&#xD;
      Pfizer Central Research protocol. Patients without AIDS who respond to therapy are observed&#xD;
      for 6 months for relapse. During therapy, samples of blood and cerebrospinal fluid (by lumbar&#xD;
      puncture) are taken periodically in order to evaluate the effectiveness of the drug&#xD;
      treatments and to identify possible toxic effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">July 1991</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>120</enrollment>
  <condition>Meningitis, Cryptococcal</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flucytosine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Immunosuppressant therapy.&#xD;
&#xD;
          -  Cyclosporin plasma concentrations should be monitored and appropriate dosage&#xD;
             adjustments made when used with amphotericin B or fluconazole.&#xD;
&#xD;
          -  Antiviral therapy.&#xD;
&#xD;
          -  Prophylaxis for Pneumocystis carinii pneumonia.&#xD;
&#xD;
          -  Treatment of intercurrent opportunistic infection as long as no investigational agent,&#xD;
             or approved agent for an investigational indication, is used.&#xD;
&#xD;
          -  Antipyretics, hydrocortisone, or meperidine to prevent or ameliorate side effects&#xD;
             associated with amphotericin B.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        - Radiation therapy for mucocutaneous Kaposi's sarcoma.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Written informed consent obtained from the patient or from the patient's legal&#xD;
             guardian.&#xD;
&#xD;
          -  One of the following:&#xD;
&#xD;
          -  (1) Tentative identification of Cryptococcus neoformans in culture of lumbar&#xD;
             cerebrospinal fluid (CSF). Results of baseline cultures need not be available when&#xD;
             therapy is begun, but therapy is discontinued if the baseline CSF culture is later&#xD;
             found to be negative for C. neoformans, or (2) Clinical and CSF findings (cell count,&#xD;
             protein, glucose) compatible with cryptococcal meningitis plus one of the following:&#xD;
&#xD;
          -  (a) Positive CSF India ink examination, (b) Culture or biopsy evidence of extraneural&#xD;
             cryptococcal infection, (c) Positive serum of CSF cryptococcal antigen test, or&#xD;
             increase in titer for previously treated patients with suspected relapse, or (d)&#xD;
             Biopsy evidence of central nervous system cryptococcal infection.&#xD;
&#xD;
          -  Treatment status of either no prior systemic antifungal therapy for cryptococcosis or&#xD;
             relapse after prior therapy. The success of prior therapy must have been documented by&#xD;
             negative CSF culture at the end of therapy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed within 4 weeks of study entry:&#xD;
&#xD;
        - Successful prior therapy for cryptococcosis, but no more than 1 mg/kg/week amphotericin&#xD;
        B.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Immunosuppressant therapy.&#xD;
&#xD;
          -  Antiviral therapy.&#xD;
&#xD;
          -  Prophylaxis for Pneumocystis carinii pneumonia.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Acute or chronic meningitis based on any etiology other than cryptococcosis.&#xD;
&#xD;
          -  History of allergy to or intolerance of imidazoles, or amphotericin B.&#xD;
&#xD;
          -  Moderate or severe liver disease defined as any one or more of the following:&#xD;
&#xD;
          -  SGOT or SGPT &gt; 5 x upper limit of normal, total bilirubin &gt; 2.5 mg/dl, prothrombin&#xD;
             time &gt; 5 seconds over control, or alkaline phosphatase &gt; 2 x upper limit of normal.&#xD;
&#xD;
          -  Comatose patients.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Drugs with low therapeutic ratios that undergo hepatic metabolism may not be used with&#xD;
             fluconazole until possible drug interactions have been clarified.&#xD;
&#xD;
          -  Coumarin-type anticoagulants.&#xD;
&#xD;
          -  Oral hypoglycemics.&#xD;
&#xD;
          -  Barbiturates.&#xD;
&#xD;
          -  Immunostimulants.&#xD;
&#xD;
          -  Investigational drugs or approved (licensed) drugs for investigational indications.&#xD;
&#xD;
          -  Systemic antifungal agent other than the assigned study drug.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Lymphocyte replacement.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  More than 1 mg/kg/week amphotericin B.&#xD;
&#xD;
        Patients unlikely to survive more than 2 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armstrong D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331361013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Municipal Hosp Ctr/Jacobi Med Ctr</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mem Sloan - Kettering Cancer Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>275997215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julio Arroyo</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Powderly WG. Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996 May;22 Suppl 2:S119-23. doi: 10.1093/clinids/22.supplement_2.s119.</citation>
    <PMID>8722838</PMID>
  </reference>
  <reference>
    <citation>Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1994 May;18(5):789-92. doi: 10.1093/clinids/18.5.789.</citation>
    <PMID>8075272</PMID>
  </reference>
  <reference>
    <citation>Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992 Jan 9;326(2):83-9. doi: 10.1056/NEJM199201093260202.</citation>
    <PMID>1727236</PMID>
  </reference>
  <verification_date>July 1991</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>March 11, 2011</last_update_submitted>
  <last_update_submitted_qc>March 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2011</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Meningitis</keyword>
  <keyword>Injections, Intravenous</keyword>
  <keyword>Cryptococcus neoformans</keyword>
  <keyword>Cryptococcosis</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Fluconazole</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Amphotericin B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Flucytosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

